NICE (UK): Deuruxolitinib can be used, within its marketing authorisation, as an option to treat severe alopecia areata in adults. Deuruxolitinib can only be used if the company… read more.
According to the MHRA website, the MHRA approved Retifanlimab (Zynyz) as the first treatment given to adults with advanced Merkel cell skin cancer that has spread or returned… read more.
Amneal Pharmaceuticals announced that it has received FDA approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100… read more.
Shionogi & Co announced the FDA has accepted a Supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of… read more.
Novo Nordisk announced that the European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI… read more.
NICE (UK): Atogepant can be used as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines: i) at… read more.
Camurus announced that the FDA has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with… read more.
Pfizer Inc. announced the FDA approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone… read more.
The National Institute for Health and Care Excellence (NICE) has issued thirteen Technology Appraisal decisions in June 2026, delivering nine positive recommendations, one updated recommendation, and two terminations…. read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a further nineteen positive recommendations spanning oncology, neurology, infectious disease, dermatology, cardiovascular medicine, diabetes,… read more.
United Therapeutics Corporation announced that the FDA has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nerandomilast (Jascayd) to treat adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
